The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
- PMID: 20451870
- PMCID: PMC2920531
- DOI: 10.1016/j.jalz.2010.03.003
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
Abstract
Background: This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core.
Methods: The Core has supervised the acquisition, quality control, and analysis of longitudinal [(18)F]fluorodeoxyglucose PET (FDG-PET) data in approximately half of the ADNI cohort. In an "add on" study, approximately 100 subjects also underwent scanning with [(11)C] Pittsburgh compound B PET for amyloid imaging. The Core developed quality control procedures and standardized image acquisition by developing an imaging protocol that has been widely adopted in academic and pharmaceutical industry studies. Data processing provides users with scans that have identical orientation and resolution characteristics despite acquisition on multiple scanner models. The Core labs have used many different approaches to characterize differences between subject groups (Alzheimer's disease, mild cognitive impairment, controls), to examine longitudinal change over time in glucose metabolism and amyloid deposition, and to assess the use of FDG-PET as a potential outcome measure in clinical trials.
Results: ADNI data indicate that FDG-PET increases statistical power over traditional cognitive measures, might aid subject selection, and could substantially reduce the sample size in a clinical trial. Pittsburgh compound B PET data showed expected group differences, and identified subjects with significant annual increases in amyloid load across the subject groups. The next activities of the PET core in ADNI will entail developing standardized protocols for amyloid imaging using the [(18)F]-labeled amyloid imaging agent AV45, which can be delivered to virtually all ADNI sites.
Conclusions: ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia.
Copyright 2010 The Alzheimer
Conflict of interest statement
GE Healthcare holds a license agreement with the University of Pittsburgh based on the PIB technology described in this manuscript. Dr. Mathis is a co-inventor of PIB and, as such, has a financial interest in this license agreement. GE Healthcare had no role in the design or interpretation of results or preparation of this manuscript.
Figures







Similar articles
-
Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15. Neurobiol Aging. 2014. PMID: 23954175
-
Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.Ann Nucl Med. 2020 Feb;34(2):108-118. doi: 10.1007/s12149-019-01420-2. Epub 2019 Nov 20. Ann Nucl Med. 2020. PMID: 31749127 Free PMC article.
-
Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28. Eur J Nucl Med Mol Imaging. 2012. PMID: 22926714
-
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.Alzheimers Dement. 2015 Jul;11(7):757-71. doi: 10.1016/j.jalz.2015.05.001. Alzheimers Dement. 2015. PMID: 26194311 Free PMC article. Review.
-
The ADNI PET Core at 20.Alzheimers Dement. 2024 Oct;20(10):7340-7349. doi: 10.1002/alz.14165. Epub 2024 Aug 6. Alzheimers Dement. 2024. PMID: 39108002 Free PMC article. Review.
Cited by
-
CSF TNF-α Levels Were Associated with Longitudinal Change in Brain Glucose Metabolism Among Non-Demented Older People.Neuropsychiatr Dis Treat. 2021 May 26;17:1659-1666. doi: 10.2147/NDT.S291020. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34079263 Free PMC article.
-
Machine learning methods to predict amyloid positivity using domain scores from cognitive tests.Sci Rep. 2021 Mar 1;11(1):4822. doi: 10.1038/s41598-021-83911-9. Sci Rep. 2021. PMID: 33649452 Free PMC article.
-
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Alzheimers Res Ther. 2011 Dec 2;3(6):34. doi: 10.1186/alzrt96. Alzheimers Res Ther. 2011. PMID: 22136152 Free PMC article.
-
Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease.Cereb Cortex. 2014 Apr;24(4):978-88. doi: 10.1093/cercor/bhs381. Epub 2012 Dec 12. Cereb Cortex. 2014. PMID: 23236200 Free PMC article.
-
Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease.Brain Imaging Behav. 2012 Dec;6(4):610-20. doi: 10.1007/s11682-012-9177-0. Brain Imaging Behav. 2012. PMID: 22648764 Free PMC article.
References
-
- Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–1248. - PubMed